

A Fluoroquinolone-Resistant *Escherichia coli* Clinical Isolate without Quinolone Resistance-Determining Region Mutations Found in Japan

Toyotaka Sato, Shin-ichi Yokota, Ikuo Uchida, Torahiko Okubo, Kanako Ishihara, Nobuhiro Fujii and Yutaka Tamura
Antimicrob. Agents Chemother. 2011, 55(8):3964. DOI:
10.1128/AAC.00532-11.
Published Ahead of Print 13 June 2011.

Updated information and services can be found at:
<http://aac.asm.org/content/55/8/3964>

	<i>These include:</i>
REFERENCES	This article cites 6 articles, 6 of which can be accessed free at: http://aac.asm.org/content/55/8/3964#ref-list-1
CONTENT ALERTS	Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

A Fluoroquinolone-Resistant *Escherichia coli* Clinical Isolate without Quinolone Resistance-Determining Region Mutations Found in Japan[∇]

Fluoroquinolones are broad-spectrum and highly bactericidal antimicrobials agents that are used to treat various bacterial infections. *Escherichia coli* infections, especially in the urinary tract, are frequently treated with fluoroquinolones, and fluoroquinolone resistance has increased in the clinical field. Fluoroquinolone resistance is caused mainly by chromosomal mutations in the quinolone resistance-determining region (QRDR) of *gyrA* and *gyrB*, which encode DNA gyrase subunits, and *parC* and *parE*, which encode topoisomerase IV subunits. Moreover, plasmid-mediated quinolone resistance (PMQR) genes have been reported in Gram-negative bacteria, including *E. coli*. The acquisition of PMQR genes alone results in a low level of fluoroquinolone resistance and does not lead to MICs exceeding the breakpoints of these agents.

We isolated an *E. coli* strain, named HUE1, from the urinary catheter of a 77-year-old female patient in 2008 at Hokkaido University Hospital (Sapporo, Japan). The multilocus sequence type of this microorganism was ST171, and the phylogenetic group was A. The MICs of ciprofloxacin (CIP), levofloxacin (LVX), and nalidixic acid (NAL) exceeded the resistance breakpoints proposed by the Clinical and Laboratory Standards Institute (CLSI) (Table 1). The CLSI breakpoint for LVX is ≤ 2 $\mu\text{g/ml}$ susceptible and ≥ 8 $\mu\text{g/ml}$ resistant, that for CIP is ≤ 1 $\mu\text{g/ml}$ susceptible and ≥ 4 $\mu\text{g/ml}$ resistant, and that for NAL is ≤ 8 $\mu\text{g/ml}$ susceptible and ≥ 32 $\mu\text{g/ml}$ resistant (2). However, direct sequencing did not reveal any mutations in the QRDR of *gyrA*, *parC*, *parE*, or *gyrB*. We then screened for PMQR genes *qnrS*, *qnrA*, *qnrB*, *qnrC*, *qnrD*, *aac(6′)-Ib-cr*, *qepA*, and *oqxAB* by PCR. HUE1 was positive for *qnrS* and *oqxAB* (Table 1).

OqxAB is a new plasmid-encoded efflux pump belonging to the RND type and was first found in *E. coli* from swine manure

in 2003 (6). It confers resistance to several antimicrobial agents, such as olaquinox, trimethoprim, and chloramphenicol, and a slight decrease in susceptibility to fluoroquinolones (3). Isolation of *oqxAB*-harboring *Enterobacteriaceae* has been reported only in Sweden and Denmark, South Korea, and China (3, 5, 7), and isolates derived from human patients have been reported only in South Korea. This letter provides the first report of *oqxAB*-harboring *E. coli* in Japan. Zhao et al. reported the isolation of *E. coli* harboring both *qnrS* and *oqxAB* from pigs in China (7). These isolates showed no mutations in the QRDR of *gyrA* and *parC*, however, mutations in that of *parE* and *gyrB* have not been determined. These isolates showed CIP MICs of 1 to 2 $\mu\text{g/ml}$, and they are therefore susceptible or intermediate according to the CLSI breakpoints.

OqxAB and *QnrS* increase the MIC of CIP approximately 32-fold and 64-fold, respectively (1, 5). These reports suggest that fluoroquinolone resistance in HUE1 without mutations in QRDR is caused by the concomitant presence of *oqxAB* and *qnrS*. However, other mechanisms may be associated with fluoroquinolone resistance in HUE1; therefore, further investigations are needed.

In conclusion, we present the first report of fluoroquinolone resistance in an *E. coli* isolate that is independent of mutations in the QRDR. The isolate harbored two PMQR genes, *qnrS* and *oqxAB*.

We thank Hirotsugu Akizawa for providing *E. coli* clinical isolates.

This study was supported in part by a grant-in-aid from the Japanese Ministry of Health, Labor and Welfare (H21-Shokuhin-Ippan-013) and a grant from the Japan Ministry of Education, Culture, Sports, Science, and Technology for the program of developing supporting systems for upgrading education and research.

TABLE 1. Detection of fluoroquinolone susceptibility, QRDR mutations, and PMQRs in HUE1

Strain	QRDR mutations				PCR			MIC ($\mu\text{g/ml}$) ^b					
	<i>gyrA</i>	<i>parC</i>	<i>parE</i>	<i>gyrB</i>	<i>oqxA</i>	<i>oqxB</i>	<i>qnrS</i>	ENR	CIP	LVX	PUR	STX	NAL
HUE1	WT ^a	WT	WT	WT	+	+	+	8	4	8	4	2	128

^a WT, wild type.

^b ENR, enrofloxacin; PUR, prulifloxacin; STX, sitafloxacin.

REFERENCES

1. **Cerquetti, M., et al.** 2009. First report of plasmid-mediated quinolone resistance determinant *qnrS1* in an *Escherichia coli* strain of animal origin in Italy. *Antimicrob. Agents Chemother.* **53**:3112–3114.
2. **Clinical and Laboratory Standards Institute.** 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—8th edition. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
3. **Hansen, L. H., E. Johannesen, M. Burmolle, A. H. Sørensen, and S. J. Sørensen.** 2004. Plasmid-encoded multidrug efflux pump conferring resistance to olaquinoxid in *Escherichia coli*. *Antimicrob. Agents Chemother.* **48**:3332–3337.
4. **Hansen, L. H., L. B. Jensen, H. I. Sørensen, and S. J. Sørensen.** 2007. Substrate specificity of the OqxAB multidrug resistance pump in *Escherichia coli* and selected enteric bacteria. *J. Antimicrob. Chemother.* **60**:145–147.
5. **Kim, H. B., et al.** 2009. *oqxAB* encoding a multidrug efflux pump in human clinical isolates of *Enterobacteriaceae*. *Antimicrob. Agents Chemother.* **53**:3582–3584.
6. **Sørensen, A. H., L. H. Hansen, E. Johannesen, and S. J. Sørensen.** 2003. Conjugative plasmid conferring resistance to olaquinoxid. *Antimicrob. Agents Chemother.* **47**:798–799.
7. **Zhao, J. J., et al.** 2010. Prevalence and dissemination of *oqxAB* in *Escherichia coli* isolates from animals, farmworkers, and the environment. *Antimicrob. Agents Chemother.* **54**:4219–4224.

Toyotaka Sato

*Laboratory of Food Microbiology and Food Safety
Department of Health and Environmental Sciences
School of Veterinary Medicine
Rakuno Gakuen University
Ebetsu, Hokkaido, Japan*

Shin-ichi Yokota

*Department of Microbiology
Sapporo Medical University School of Medicine
Sapporo, Japan*

Ikuo Uchida

*Hokkaido Research Station
National Institute of Animal Health
Sapporo, Japan*

Torahiko Okubo

Kanako Ishihara
*Laboratory of Food Microbiology and Food Safety
Department of Health and Environmental Sciences
School of Veterinary Medicine
Rakuno Gakuen University
Ebetsu, Hokkaido, Japan*

Nobuhiro Fujii

*Department of Microbiology
Sapporo Medical University School of Medicine
Sapporo, Japan*

Yutaka Tamura*

*582 Bunkyo-dai-Midorimachi
Ebetsu, Hokkaido 069-8501, Japan*

*Phone and fax: 81-11-388-4890
E-mail: tamuray@rakuno.ac.jp

^v Published ahead of print on 13 June 2011.